ARJUMAND JAFFRI: Open Payments
NPI 1205976602 · SMITHVILLE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$439 in 26 payments from 9 companies in 2025. Trend: 2023 $343 · 2024 $547 · 2025 $439
Food & beverage: $431Education: $8
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $138 |
| ABBVIE INC. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Alkermes, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: REXULTI, VRAYLAR, FANAPT, COBENFY, ABILIFY MAINTENA, ARISTADA, ABILIFY ASIMTUFII, CAPLYTA.
Industry payments across MO — which companies pay providers there.
